60 results about "Sulphonilamide" patented technology

The invention discloses an N-phenylbenzenesulfonamide compound as well as a preparation method and application thereof. The compound disclosed by the invention is shown as a formula (I). The compound is an LDHA enzyme inhibitor, is a sulfonamide compound with anti-tumor activity, shows good anti-tumor activity at the cellular level, has good safety and can be used for preparing anti-tumor drugs. # imgabs0 #

The present invention (named: a class of aminonaphthoquinone derivatives and their preparation and sterilization, weeding and algae killing uses) relates to 33 2-chloro-3-aminonaphthoquinone formate, urea, amide and sulfonamide derivatives and their preparation methods, as well as their uses in sterilization, weeding and algae killing. The 33 2-chloro-3-aminonaphthoquinone formate, urea, amide and sulfonamide derivatives are generated by reacting 2,3-dichloronaphthoquinone with potassium cyanate, substituted alcohol or amine, or with sulfonamide; or by reacting 2-chloro-3-aminonaphthoquinone with different amides. These compounds can be used as fungicides to control tomato gray mold, or as herbicides to control weeds such as Amaranthus retroflexus and Crabgrass, or as algaecides to control algae.

The present invention discloses the use of a benzenesulfonamide compound in the preparation of a medicament for preventing and / or treating osteoarthritis. This invention proposes for the first time the use of a benzenesulfonamide compound in a medicament for preventing and / or treating osteoarthritis. Experiments have shown that administration of a benzenesulfonamide compound can significantly improve joint swelling and wear in osteoarthritis mice; at the same time, the benzenesulfonamide compound can significantly reduce cartilage damage and inhibit the progression of joint fibrosis in osteoarthritis mice; in addition, the benzenesulfonamide compound significantly inhibits the expression of inflammation-related markers in the serum of osteoarthritis model mice. The above experiments demonstrate that benzenesulfonamide compounds can improve osteoarthritis and are of great significance for the future development of drugs and the prevention and treatment of such diseases.

The invention belongs to the field of organic synthesis, and relates to a method for synthesizing beta-sulfamide. According to the method, primary amine and alkenyl sulfonyl fluoride are used as raw materials, silica gel is used as a catalyst, and a reaction is carried out in a solvent to generate the beta-sulfamide compound. Compared with a traditional method for synthesizing beta-sulfamide through a multi-step reaction, the beta-sulfamide synthesis method is easy and convenient to operate, mild in condition, low in reagent cost, easy to obtain, high in reaction yield and wide in substrate application range. The invention also discloses an application of beta-sulfamide compounds synthesized from primary amine and alkenyl sulfonyl fluoride under a silica gel catalysis condition in drug modification.

The invention discloses sulfonamide ionic liquid as well as a preparation method and application thereof. The sulfonamide ionic liquid comprises one or more of quaternary ammonium cations, quaternary phosphonium cations, trimethyl hydroxyethyl ammonium ions and protonated organic alkali. And one or more of benzene sulfonamide anions and substituted benzene sulfonamide anions; substituted benzene sulfonamide is selected as an anion for the first time, and the variety of ionic liquid is developed; the ionic liquid has the advantages of easily available raw materials, easy preparation, high thermal stability and chemical stability; the sulfonamide ionic liquid has alkalescence, can capture CO2 through chemical action, is high in capture amount and easy to desorb, and has a good recycling effect; the diluent is selected, the molecular weight is small, the chemical stability is high, and the amount of CO2 captured by each kilogram of ionic liquid can be effectively increased; the ionic liquid provided by the invention is mixed with a diluent according to a certain molar ratio for CO2 capture, so that the viscosity of a system can be effectively reduced, the mass transfer of CO2 in the system is enhanced, and the CO2 capture amount is increased.

This invention discloses 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives, their synthesis methods and applications, belonging to the field of pharmaceutical technology, and involving two series of compounds: 3-sulfonamido-2'-hydroxy-4,4',6'-trimethoxychalcone and 8,3'-disulfonamido-5,7,4'-trimethoxyflavanone, and their preparation methods. Starting with 2-hydroxy-4,6-dimethoxyacetophenone and p-anisaldehyde or 4-methoxy-3-nitrobenzaldehyde, 2'-hydroxy-4,4',6'-trimethoxychalcone or 3-amino-2'-hydroxy-4,4',6'-trimethoxychalcone intermediates were synthesized via the Claisen-Schmidt reaction. Then, through sulfonation and intramolecular Michael addition reactions, 2'-hydroxy-4,4',6'-trimethoxychalcone and 5,7,4'-trimethoxyflavanone sulfonamide derivatives were synthesized. The preparation method is simple, mild, and yields high results. In vitro and in vivo activity tests show that the derivatives disclosed in this invention have significant in vitro inhibitory activity against gastric cancer, esophageal cancer, colorectal cancer, and lung cancer cell lines, acting as inhibitors of the protein YBX1 / RPN1. Clinically, they can be applied to targeted therapy for cancers such as gastric cancer, esophageal cancer, colorectal cancer, and lung cancer.

The present application relates to the formula shown with BCA Tm agonist effect 2- (amino carbonyl) -1H-indole-5-carboxamide derivatives, its racemate or optical isomer, its solvate, or its pharmaceutically acceptable salt, and its use in the preparation of treating metabolic syndrome or obesity drugs and the use of pharmaceutical compositions containing them. Wherein, R1 is the following substituent group amide, methanol, methyl sulfonamide.

Disclosed is a pharmaceutical composition for treatment of Parkinson's disease comprising N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide represented by formula (1) or a pharmaceutically acceptable salt thereof.

The invention provides a preparation method of viltrabutine hydrochloride, and relates to the technical field of medicine synthesis. The invention relates to a preparation method of viltrobutine hydrochloride, which comprises the following steps: (1) in the presence of a catalyst, reacting 3, 4-dimethoxybenzaldehyde with tert-butyl sulfinamide to obtain a compound VC-1; (2) reacting the compound VC-1 with (3-phenyl propyl) magnesium bromide to obtain a compound VC-2; (3) reacting the compound VC-2 with acid, and neutralizing to obtain a compound VC-3; (4) reacting the compound VC-3 with formaldehyde in the presence of a reducing agent to obtain free viltrabutine; and (5) reacting the free viltrabutine with hydrogen chloride to obtain the viltrabutine hydrochloride. The invention provides a viltrabutine hydrochloride synthesis process which is high in purity, high in yield and simple and convenient to operate, the operation process is simplified, and industrial production is convenient to realize.

The application provides a preparation method of a pyrimidine sulfamide compound, and the method overcomes the defects of the prior art, such as the need of using an excessive strong base, low conversion efficiency, and more by-products, and the like, and the method is characterized in that the pyrimidine sulfamide is generated through the reaction of the combined action of a molecular sieve and a catalyst, the reaction condition is mild, the step is economical, the environment is friendly, the comprehensive production cost is low, the raw material is easy to obtain, the environment is friendly and economical, and the method is beneficial to the industrialized production of the pyrimidine sulfamide compound.

The invention belongs to the technical field of organic synthesis, and particularly discloses a method for preparing solanone, which comprises the following steps: taking 3-butene-2-ketone and isovaleraldehyde as initial raw materials, and preparing (S)-2-isopropyl-5-carbonyl hexanal in one step under the common catalysis of bivalent ruthenium and diphosphine sulfonamide chiral ligand and a catalytic amount of alkali; (S, E)-solanone is specifically obtained from the aldehyde and a Wittig reagent under the combined action of phenyl lithium and LiBr; preparing (R, E)-solanone with the opposite configuration by utilizing the chiral ligand with the opposite configuration; the (R, E)-solanone with the opposite configuration can be prepared through the chiral ligand with the opposite configuration, raw materials and reagents are simple, cheap and easy to obtain, the reaction steps are short, the yield is high, a product with high optical purity can be obtained through two steps, separation is easy, and the method is suitable for large-scale production.

The application discloses a use of a benzene sulfonamide compound in preparation of a medicine for regulating sleep, and the benzene sulfonamide compound has the following structure: the application first proposes the use of the benzene sulfonamide compound in preparation of the medicine for regulating sleep, and animal experiments show that tail vein injection of the benzene sulfonamide compound into mice can promote sleep of the mice, can significantly reduce a proportion of wake time of the mice, and can increase proportions of non-rapid eye movement sleep time and rapid eye movement sleep time.

To provide methods for producing O-substituted serine derivatives useful as pharmaceutical intermediates and sulfamidates useful for producing them with excellent regioselectivity, chemical yield, and optical purity.SOLUTION: It was discovered that a cyclic sulfamidate can be produced by reacting an amino acid derivative with a cyclization reagent. In addition, it was discovered that an O-substituted serine derivative can be produced by reacting a cyclic sulfamidate with an alcohol.SELECTED DRAWING: None

The application discloses a sulfonamide compound, a preparation method and application thereof. The compound can selectively antagonize a human and mouse NOD1 signal path, can inhibit secretion of inflammatory cytokines, and can be used for treating inflammatory diseases, in particular, gastritis caused by helicobacter pylori infection.

The present invention provides novel fluorinated cyclic derivatives of sulfonamides and sulfones useful in the treatment of various diseases and disorders associated with TRPML activity, such as neurodegenerative diseases, lysosomal storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stress or reactive oxygen substance (ROS)-related diseases, aging, etc. The invention also relates to a composition, a preparation method and application thereof.

The application discloses a 1, 2, 3-triazole sulfamide derivative, a preparation method and application thereof. The compound has a general formula (A). The synthesis method is as follows: sulfamide is used as a starting material, diazotization, azidation, and then coupling with ethyl acetoacetate to complete the docking of the triazole ring and the sulfamide, and an amide bond is introduced into the structure, and then a series of novel 1, 2, 3-triazole sulfamide derivatives are synthesized. The compounds have excellent bacteriostatic, insecticidal and fungicidal functions on escherichia coli, pseudomonas aeruginosa, salmonella typhi, staphylococcus aureus, bacillus subtilis, and fungi such as candida albicans and aspergillus niger, pests and plant pathogenic bacteria in forestry and other fields.

The invention belongs to the field of medical chemistry, and relates to a pharmaceutical composition of an internal sulfonamide compound, in particular to a pharmaceutical composition of a compound shown as a formula I or pharmaceutically acceptable salt thereof and medical application of the pharmaceutical composition. # imgabs0 #

The present application relates to the technical field of environmental functional materials, and provides a polysulfamide-metal organic framework acid-resistant nanofiltration membrane as well as a preparation method and application thereof. The present application utilizes the metal organic framework MIL-101(Cr) to regulate the interfacial polymerization process of the polysulfamide selective layer, so that the polysulfamide-metal organic framework acid-resistant nanofiltration membrane with high permeability and good acid resistance is obtained. The polysulfamide-metal organic framework acid-resistant nanofiltration membrane prepared by the present application has good stability in a strong acid solution, can continuously work in acidic wastewater, has a relatively high permeation flux, can significantly improve the separation efficiency, can efficiently recover heavy metal ions in industrial acidic wastewater, and has a good application prospect in water treatment processes. Meanwhile, the preparation method provided by the present application is simple in process, controllable in cost, and suitable for large-scale production and application.

This invention discloses a novel chiral sulfinamide monophosphine ligand based on an oxanthracene skeleton, its preparation method, and its application. The preparation method includes the following steps: (1) oxanthracene is subjected to a substitution reaction with RBr in the presence of sodium hydride and a solvent to obtain intermediate 1; (2) intermediate 1 is subjected to lithium halide exchange with butyllithium in the presence of a solvent, followed by the addition of a halogen to obtain intermediate 2; (3) intermediate 2 is subjected to halogen-metal exchange with isopropylmagnesium chloride in the presence of a solvent, followed by the addition of diphenylphosphine chloride to undergo a substitution reaction to obtain intermediate 3; (4) intermediate 3 is subjected to lithium halide exchange with butyllithium in the presence of a solvent, followed by the addition of a compound to react in the presence of a Lewis acid to obtain the chiral sulfinamide monophosphine ligand. The chiral sulfinamide monophosphine ligand prepared by this invention can be used to prepare chiral α-alkyl-α-benzyltetrahydronaphthone compounds with high yield and ee value.

The application discloses a preparation method of a chiral sulfimine compound and belongs to the technical fields of visible light catalysis and organic synthesis. N -[(9 R )-6'-methoxyoctanosyl]-8-quinolinesulfonamide as a chiral ligand, fluorobenzene as a solvent, under the action of a copper salt and an oxidant, under visible light irradiation at room temperature in a protective atmosphere, the copper salt, the sulfenamide compound and N -[(9 R )-6'-methoxyoctanosyl]-8-quinolinesulfonamide form a copper complex, the copper complex enters an excited state under visible light irradiation, cleaves the oxidant through an energy transfer or single electron transfer process, generates a highly active free radical, the free radical activates an inert carbon-hydrogen bond to generate an alkyl free radical and reacts with the sulfenamide in the copper complex, asymmetric sulfuration of the inert carbon-hydrogen bond is realized, and the chiral sulfimine compound is obtained.

Provided is an industrial hose having excellent heat resistance and excellent adhesion between a rubber layer and a reinforcing layer formed from a plated wire. An industrial hose having a rubber layer formed from a rubber composition containing the following components (A) to (D): 0.5 to 1.0 parts by mass of component (C) and 1.0 to 3.0 parts by mass of component (D) per 100 parts by mass of component (A), and having a mass ratio [(C) / (B)] of component (C) to component (B) of 0.5 to 1.0, and a reinforcing layer that is in contact with the rubber layer and is formed from a plated wire, the reinforcing layer being characterized in that the content of component (C) is 0.5 to 1.0 parts by mass per 100 parts by mass of component (A), the content of component (D) being 1.0 to 3.0 parts by mass per 100 parts by mass of component (A), and the mass ratio [(C) / (B)] of component (C) to component (B) being 0.5 to 1.0 part by mass per 100 parts by mass of component (A). The mass ratio [(D) / {(B) + (C) + (D)}] of component (D) to the total amount of components (B)-(D) is 0.3-0.6. (A) A diene rubber. And (B) at least one of a sulfenamide-based vulcanization accelerator and a thiazole-based vulcanization accelerator. And (C) N-phenyl-N-(trichloromethylthio) benzenesulfonamide. (D) sulfur.

The present disclosure relates to use of a sultam compound in treating biliary tract cancer, and specifically relates to use of a compound represented by formula I or a pharmaceutically acceptable salt thereof in treating biliary tract cancer. The compound represented by formula I or the pharmaceutically acceptable salt thereof of the present disclosure has good safety and anti-tumor activity.

A rubber composition includes a chloroprene-based rubber, 5 to 80 parts by mass of silica, 0.5 to 15 parts by mass a silane coupling agent, and 0.5 to less than 20 parts by mass of a hydrate. The rubber composition satisfies at least one of (i) and (ii): (i) the rubber composition includes 0.1 to 3.0 parts by mass of 3-methyl-thiazolidine-2-thione; (ii) the rubber composition includes 0.1 to 3.0 parts by mass of compound A that is at least one of a thiourea-based compound, 3-methyl-thiazolidine-2-thione, and di(5-mercapto-1,3,4-thiadiazol-2-yl) disulfide; and 0.01 to 3.0 parts by mass of compound B that is at least one of a thiuram-based compound, a sulfenamide-based compound, a thiazole-based compound, a guanidine-based compound, a benzimidazole-based compound, N-phenyl-N-(trichloromethylthio)benzenesulfonamide, and a diazabicycloundecene-based compound.

The invention discloses a macromolecule capable of promoting intake of anticancer drugs, a composition and application of the macromolecule in preparation of the anticancer drugs. The macromolecule contains a plurality of guanidino groups and a plurality of sulfamide groups, the macromolecule has the average molecular weight smaller than or equal to 50,000 Da, and the zeta potential of the macromolecule is smaller than or equal to + 2 mV under the simulated normal physiological condition (pH 7.4) and larger than or equal to + 5 mV under the simulated tumor subacid environment (pH 6.5-6.8). The macromolecules can promote the aggregation and permeation of the anticancer drugs in tumor tissues and promote the anticancer drugs to enter cancer cells, and the anticancer effect of the anticancer drugs can be improved when the macromolecules are combined with the anticancer drugs, so that the anticancer effect is remarkably improved when the macromolecules are combined with the anticancer drugs under the same dosage of the anticancer drugs, and the anticancer effect of the anticancer drugs is improved. Or the toxic and side effects of the anticancer drugs are greatly reduced by combining with the macromolecules under the condition of lower dosage of the anticancer drugs.

Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of a compound, which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or hydrate thereof.

The present disclosure relates to crystalline forms of sulfamide derivatives and methods for preparing same. Specifically, the present disclosure provides a novel crystalline form of the compound represented by Formula 1 and methods for preparing same. [Formula 1] TIFF2026505853000024.tif34168